Dr. Matt Barnes

Executive Officer, Vice President, President of Heptares Therapeutics Ltd., and Head of UK R&D

Matt joined Sosei Heptares in 2016 as Head of Molecular Pharmacology and subsequently Senior Vice President, Drug Discovery and Head of R&D Portfolio Management. Matt has over 20 years’ experience in the biotech and pharmaceutical industry and previously held positions of increasing seniority at Takeda in Cambridge, UK and at Celltech Ltd (now UCB). He has a BSc in Biochemistry and a PhD in Pharmacology from Newcastle University in the UK.

Matt was appointed as President of Heptares Therapeutics Ltd. in March 2022.